Improved Outcomes With Alemtuzumab Following Switch From SC IFNB-1a: 6-Year Follow-up of CARE-MS II Patients With Active RRMS (TOPAZ Study)
2019
- Correction
- Cite
- Save
- Machine Reading By IdeaReader
0
References
0
Citations
NaN
KQI